NICE guidance on type-2 diabetes

Draft NICE guidelines on type-2 diabetes have backed second-line use of DPP-4 inhibitors and glitazones in some patients.

The recommendations cover DPP-4 inhibitors (sitagliptin and vildagliptin), glitazones (pioglitazone and rosiglitazone) and exenatide, as well as when to start insulin therapy.

Metformin and a sulphonylurea remain preferred first- and second-line agents, but for patients not suitable for this treatment and who are uncontrolled on one of them, a DPP-4 inhibitor or a glitazone is recommended as an add-on therapy.

Exenatide can be added to metformin and a sulphonylurea for obese patients and those unsuitable for insulin therapy.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in